Tab Application Banner
  • Users Online: 483
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Prescribing patterns and safety of biologics in immune-mediated rheumatic diseases: Karnataka biologics cohort study group experience

Shobha Vineeta, Rao Vijay, Desai Anu Mohan, Jois Ramesh, Srikantiah Chandrashekara, Dharmanand B G, Kumar Sharath, Kumar Pradeep, Dharmapalaiah Chethana, Mahendranath K M, Prasad Shiva, Daware Manisha, Singh Yogesh, Karjigi Uma

Year : 2019| Volume: 14| Issue : 1 | Page no: 17-20

   This article has been cited by
 
1 The perennial search for alternatives to corticosteroids in rheumatology: is there light at the end of the tunnel?
Durga Prasanna Misra,Vikas Agarwal
Clinical Rheumatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
2 Is it time to say goodbye to weekly rituximab in ANCA vasculitis?
Benzeeta Pinto,Aadhaar Dhooria
Clinical Rheumatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
3 Response to: Biosimilars for vasculitis: promise requires validation by quality studies
Sakshi Mittal,G. S. R. S. N. K. Naidu,Aman Sharma
Clinical Rheumatology. 2020;
[Pubmed]  [Google Scholar] [DOI]
4 Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
Sanjiv Kapoor,Viswanath V. Kaushik,Rahul Jain,Vijay K.R. Rao,Mihir Gharia
ACR Open Rheumatology. 2019;
[Pubmed]  [Google Scholar] [DOI]
5 Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Sanjiv Kapoor,Viswanath V. Kaushik,Rahul Jain,Vijay Rao,Mihir Gharia
Rheumatology and Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article